Coherus Oncology Inc

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

• ↑Q1 2026 Lactorsi revenue rose 61% YoY to $11.8M, fueled by a 21% increase in new patient starts.
• ↑Management projects Lactorsi will reach $15M quarterly by late 2026 and $175M in annual sales by 2028.
• ↓June 2026 downgrade followed Q2 EPS estimate cut from $0.08 to -$0.12, undermining investor confidence.